SMMT Stock Chart & Stats
$262.00
$0.00(0.00%)
At close: 4:00 PM EDT
$262.00
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$230.00 - $430.00
Previous CloseN/A
Volume0.00
Average Volume (3M)1.00
Market Cap
$231.38B
Enterprise Value$10.67B
Total Cash (Recent Filing)$690.68M
Total Debt (Recent Filing)$20.38M
Price to Earnings (P/E)―
Beta0.35
Next Earnings
Nov 11, 2026EPS Estimate
-5.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.12
Shares Outstanding799,726,440
10 Day Avg. Volume3
30 Day Avg. Volume1
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)26.74
Price to Sales (P/S)0.00
P/FCF Ratio-54.45
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$510.07Price Target Upside94.68% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering14
EPS Forecast (FY)-21.87
Revenue Forecast (FY)$68.45M
Bulls Say, Bears Say
Bulls Say
Phase III Clinical EfficacyConsistent efficacy across multiple Phase III studies supports ivonescimab’s potential differentiation in oncology rather than reliance on a single trial. Repeated survival signals can strengthen regulatory, partnering, and commercial prospects across several cancer indications over the next several quarters.
Strategic AstraZeneca PartnershipA large strategic investment from AstraZeneca provides external validation of ivonescimab and strengthens Summit’s capitalization for late-stage development. The accompanying combination work also expands access to a major oncology partner and may improve the asset’s competitive positioning.
Broadening Oncology PipelineA broad, multi-indication development program gives Summit several potential paths to create long-term value from ivonescimab. Multiple trials and external collaborations diversify clinical opportunities, increase patient and investigator exposure, and support platform-like strategic relevance.
Bears Say
Pre-revenue And Large LossesWithout a meaningful revenue base, Summit’s financial outlook depends heavily on clinical and regulatory success rather than established commercial cash flows. Continued large losses limit earnings visibility and mean that any delay in development or approval could extend the period before profitability.
High And Rising Cash BurnHeavy operating cash consumption reduces the time available to fund Summit’s extensive clinical program from existing resources. Rising trial and research spending can accelerate financing needs, increase execution pressure, and make sustained progress dependent on continued access to external capital.
Regulatory And Statistical UncertaintyThe pending FDA decision remains a material business risk because approval depends on an overall-survival standard that has not yet received agency feedback. Multiple interim analyses, differing regional maturity, and possible requests or delays could complicate interpretation and timing.
Summit Therapeutics News
SMMT FAQ
What was Summit Therapeutics’s price range in the past 12 months?
Summit Therapeutics lowest stock price was $230.00 and its highest was $430.00 in the past 12 months.
What is Summit Therapeutics’s market cap?
Summit Therapeutics’s market cap is $231.38B.
When is Summit Therapeutics’s upcoming earnings report date?
Summit Therapeutics’s upcoming earnings report date is Nov 11, 2026 which is in 15 days.
How were Summit Therapeutics’s earnings last quarter?
Summit Therapeutics released its earnings results on Jul 23, 2026. The company reported -$5.15 earnings per share for the quarter, missing the consensus estimate of -$5.039 by -$0.11.
Is Summit Therapeutics overvalued?
According to Wall Street analysts Summit Therapeutics’s price is currently Undervalued.
Does Summit Therapeutics pay dividends?
Summit Therapeutics does not currently pay dividends.
What is Summit Therapeutics’s EPS estimate?
Summit Therapeutics’s EPS estimate is -5.17.
How many shares outstanding does Summit Therapeutics have?
Summit Therapeutics has 799,726,440 shares outstanding.
What happened to Summit Therapeutics’s price movement after its last earnings report?
Summit Therapeutics reported an EPS of -$5.15 in its last earnings report, missing expectations of -$5.039. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Summit Therapeutics?
Currently, no hedge funds are holding shares in MX:SMMT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Summit Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$510.07 (94.68% Upside)
$510.07 (94.68% Upside)
Blogger Sentiment
Bullish
MX:SMMT Sentiment 88%
Sector Average 67%
Sector Average 67%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-17.49%
12-Months-Change
Fundamentals
Return on Equity
-204.33%
Trailing 12-Months
Asset Growth
132.13%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Summit Therapeutics
Summit Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing therapeutic solutions, primarily targeting infectious diseases across the United States and Latin America. The company's clinical development pipeline is heavily concentrated on therapies for Clostridioides difficile infection (CDI). Its flagship product candidate, ridinilazole, is an orally administered small molecule antibiotic currently advancing through Phase III clinical trials as a treatment for CDI. Beyond its lead asset, Summit Therapeutics is also progressing SMT-738, designed to combat multidrug-resistant infections, notably carbapenem-resistant Enterobacteriaceae (CRE). Additionally, its DDS-04 series represents a potential therapeutic avenue for various infections caused by the Enterobacteriaceae family of bacteria. Established in 2003, the company maintains its headquarters in Cambridge, Massachusetts.
SMMT Company Deck
SMMT Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized substantial clinical progress for ivonescimab — multiple positive Phase III PFS readouts, overall survival hazard ratios consistently under 0.80, extensive global clinical activity, commercial exposure in China, and a strong cash balance with no debt. Key near-term catalysts include the FDA PDUFA date (Nov 14, 2026) and upcoming HARMONi-3 interim analyses. Offsetting risks include accelerating operating costs and cash burn, reliance on ATM financings, regulatory uncertainty around statistically significant OS for approval, and the statistical/operational complexity introduced by multiple interim OS looks and regional maturity differences. Overall, the positives around clinical data and pipeline breadth outweigh the financial and regulatory risks presented on the call.View all MX:SMMT earnings summariesSMMT Stock 12 Month Forecast
Average Price Target
$510.07
▲(94.68% Upside)
Technical Analysis
ImmunityBio
―
Zai Lab
―
Arcus Biosciences
―
Immunocore Holdings
―
CG Oncology, Inc.
―